Craneware (LSE:CRW), the Edinburgh-based provider of healthcare financial performance software for the US market, warned on 3 July 2026 that its results for the year to 30 June 2026 would fall below market expectations. The shares fell as much as 22% that day to around £11.54, leaving them down about 40% in 2026 with a Market Value of roughly £395 million.

What the company does

Craneware sells software and services that help US hospitals manage Revenue and costs. A significant part of its recent growth has come from products linked to the US 340B drug pricing programme, which allows eligible providers to buy certain medicines at reduced prices. Chief executive Keith Neilson leads the group, which reports in US dollars.

The July trading update

The board guided to revenue of US$205 million to US$208 million and adjusted EBITDA of US$65 million to US$67 million for fiscal 2026, both broadly in line with the prior year. That compared unfavourably with what the market had expected. The company blamed the timing of eligible 340B activity and the deferral of some significant enterprise contracts, which it now expects to contribute in fiscal 2027.

On the 340B side, outstanding qualifying drug purchases in the pipeline were about US$500 million. Pharmaceutical manufacturers have expanded Supply restrictions on certain 340B-priced medicines, which slowed how quickly those opportunities turned into revenue. Because a significant share of revenue is recognised when the customer receives the benefit of the eligible drugs, rather than when an opportunity is identified, delays push income into later periods. The board called it a short-term timing impact, saying customer retention, Demand and cash generation remained solid. Mr Neilson said he was disappointed not to deliver the growth LSE:CRW had expected.

Earlier in the year

Craneware issued a first-half trading update and notice of results on 20 January 2026 and published interim results for the first half of fiscal 2026 afterwards. Analyst commentary described the January update as showing a solid performance. LSE:CRW has also made transactions in its own shares.

Takeover history

In June 2025 Craneware rejected a proposal from Bain Capital at £26.50 per share, which would have valued it at about £939.4 million. The current share price, around £11.54 after the July fall, is far below that proposal, a fact that frames how investors view the recent setback.

Sector and index context

Craneware (LSE:CRW) is among the larger technology companies on the FTSE AIM All Share Index. Healthcare software is typically valued on visibility of recurring revenue, so any slippage in revenue timing is punished heavily, particularly where regulation and drug-maker policy sit outside management control.

Key risks

The principal risk is the 340B environment: manufacturer restrictions could continue, regulatory changes might alter the programme, and conversion of the pipeline is uncertain. Deferred enterprise contracts may slip again. Concentration in a single country and a single policy theme leaves the group exposed. Another guidance miss would probably damage confidence further, given the share price fall.

What to watch next

The September 2026 full-year results should reveal the exact figures, annual recurring revenue, cash and guidance for fiscal 2027. Investors will also look for evidence that deferred contracts are signing and that the 340B pipeline is converting, and for any renewed corporate interest.